



The Illinois Medical Bulletin



The Association Between Vitamin D Deficiency and Systemic Lupus Erythematosus: A Review of Foundational Immunological and Clinical Evidence

¹A.Bondy, ²A. Borah

^{1,2} University of Illinois College of Medicine

Corresponding Email : drbondy28743@gmail.com

Article History :

Received date : 2013/10/12
Revised date : 2013/11/28
Accepted date : 2013/12/09
Published date : 2014/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease driven by a loss of immune tolerance. Prior to 2010, a paradigm shift was occurring in the understanding of Vitamin D, moving beyond its classical role in bone metabolism to recognise its function as a potent immunomodulator. This review synthesises the foundational literature published before 2010 that explored the relationship between Vitamin D status and the pathogenesis and activity of SLE.

Literature Review: A substantial body of basic science research from this era established the immunological rationale for a link. The Vitamin D receptor was identified on key immune cells, including T cells, B cells, and antigen-presenting cells. In-vitro studies demonstrated that the active form of Vitamin D could suppress pro-inflammatory T-cell responses, inhibit B-cell proliferation and antibody production, and promote regulatory immune pathways. This was complemented by a growing number of clinical observational studies that consistently reported

a high prevalence of Vitamin D deficiency and insufficiency in SLE patient cohorts. Furthermore, early cross-sectional studies began to uncover an inverse correlation between serum Vitamin D levels and SLE disease activity scores, suggesting a clinically relevant relationship.

Conclusion: The pre-2010 immunological and clinical evidence provides a strong basis for an association between Vitamin D deficiency and SLE. Foundational research established Vitamin D as a key regulator of immune function, while clinical studies confirmed its widespread deficiency in lupus patients and suggested a link to disease severity. This body of work positioned Vitamin D status as a plausible modifiable environmental factor in SLE.

Keywords: Vitamin D Deficiency, Systemic Lupus Erythematosus (SLE), Autoimmunity, Immunomodulation, Disease Activity.

INTRODUCTION

Systemic Lupus Erythematosus (SLE) is a prototypical systemic autoimmune disease characterised by the production of autoantibodies against nuclear antigens, leading to widespread inflammation and multi-organ damage. Its pathogenesis is multifactorial, involving a complex interplay between genetic susceptibility and environmental triggers. For decades, research sought to identify modifiable environmental factors that could influence the development or severity of the disease.

Concurrently, the scientific understanding of Vitamin D was undergoing a significant expansion. Traditionally recognised for its indispensable role in calcium homeostasis and bone health, a new body of evidence emerging before 2010 began to characterise Vitamin D as a potent hormone with profound effects on the immune system. This non-classical function suggested that its deficiency might play a role in the dysregulation that underpins autoimmune diseases like SLE. This literature review aims to explore and synthesise the foundational scientific and clinical evidence published prior to 2010 that established the association between Vitamin D deficiency and the risk and activity of SLE.

LITERATURE REVIEW

The link between Vitamin D and SLE explored in the literature before 2010 can be understood through two primary lines of evidence: the basic science of its immunomodulatory effects and the clinical observations in patient populations.

The scientific rationale for Vitamin D's role in autoimmunity was firmly established during this period. It was discovered that the Vitamin D receptor (VDR) is expressed not only in classical target tissues like the intestine and bone, but also on a wide variety of immune cells, including activated T and B lymphocytes, macrophages, and dendritic cells (Adorini and Penna, 2008). This discovery implied a direct role in regulating immune responses. Subsequent in-vitro research demonstrated that 1,25-dihydroxyvitamin D, the active form of Vitamin D, exerts powerful immunomodulatory effects. These include the inhibition of T-helper 1 (Th1) cell proliferation and the suppression of their key pro-inflammatory cytokines, such as interferon-gamma (IFN- γ) and interleukin-2 (IL-2), both of which are implicated in lupus pathogenesis. Conversely, Vitamin D was shown to promote the development of more tolerogenic T-helper 2 (Th2) cells and regulatory T-cells (Tregs), which are crucial for maintaining self-tolerance (Cantorna et al., 2004). Furthermore, Vitamin D was found to directly inhibit B-cell proliferation, differentiation into plasma cells, and the production of immunoglobulins, targeting the very source of the autoantibodies that define SLE.

Building on this strong biological plausibility, clinical researchers began to investigate Vitamin D status in SLE patients. A consistent finding from numerous observational and cross-sectional studies published in the 2000s was the remarkably high prevalence of Vitamin D deficiency and insufficiency in SLE cohorts worldwide, far exceeding that of age-matched healthy controls (Kamen and Cooper, 2006; Huisman et al., 2001). While this was partly attributed to disease-specific factors, such as photosensitivity leading to rigorous sun avoidance and the use of corticosteroids, the potential for the deficiency to be a contributing factor to the disease, rather than just a consequence, became a major point of interest.

This led to studies investigating a direct link between Vitamin D levels and disease activity. Early but influential studies began to report a significant inverse correlation between serum 25-hydroxyvitamin D levels—the standard measure of Vitamin D status—and validated measures of SLE disease activity, such as the SLE Disease Activity Index (SLEDAI). Although these studies were largely cross-sectional and could not prove causation, they provided the first clinical evidence that lower Vitamin D levels were associated with more active disease,

suggesting a potentially protective role for Vitamin D sufficiency (Kamen et al., 2006). This clinical association, combined with the immunologic data, provided a compelling argument for further investigation.

CONCLUSION

The literature published before 2010 laid a robust foundation for understanding the significant relationship between Vitamin D status and Systemic Lupus Erythematosus. Foundational basic science research successfully repositioned Vitamin D from a simple nutrient for bone health to a sophisticated immunomodulatory hormone capable of influencing the very cellular pathways that are dysregulated in SLE. This mechanistic evidence provided a strong biological rationale for its potential role in autoimmunity.

This was strongly supported by consistent clinical findings of a high prevalence of Vitamin D deficiency in lupus patients and, more importantly, by emerging data demonstrating an inverse correlation between Vitamin D levels and disease activity. While the need for prospective, randomised controlled trials to prove that supplementation could alter the course of the disease was clear, the body of work from this era was pivotal. It successfully established Vitamin D deficiency as a highly plausible, modifiable environmental factor involved in the complex pathogenesis of SLE, opening a new and promising avenue for research and potential therapeutic strategies.

REFERENCES

- Adorini, L. and Penna, G. (2008) 'Control of autoimmune diseases by the vitamin D endocrine system', *Nature Clinical Practice Rheumatology*, 4(8), pp. 404-412.
- Cantorna, M.T., Zhu, Y., Froicu, M. and Wittke, A. (2004) 'Vitamin D status, 1,25-dihydroxyvitamin D₃, and the immune system', *The American Journal of Clinical Nutrition*, 80(6 Suppl), pp. 1717S-1720S.
- Holick, M.F. (2007) 'Vitamin D deficiency', *New England Journal of Medicine*, 357(3), pp. 266-281.
- Huisman, A.M., White, K.P., Algra, A., Harth, M., Vieth, R., Jacobs, J.W., Bijlsma, J.W. and Bell, D.A. (2001) 'Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia', *The Journal of Rheumatology*, 28(11), pp. 2535-2539.

Kamen, D.L. and Cooper, G.S. (2006) 'Vitamin D and cardiovascular disease in systemic lupus erythematosus', *Current Opinion in Rheumatology*, 18(5), pp. 471-476.

Kamen, D.L., Cooper, G.S., Bouali, H., Shaftman, S.R., Hollis, B.W. and Gilkeson, G.S. (2006) 'Vitamin D deficiency in systemic lupus erythematosus', *Autoimmunity Reviews*, 5(2), pp. 114-117.